MNOV - メディシノバ （MediciNova Inc.）

DelveInsight''s "Alcohol Use Disorder Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Alcohol Use Disorder Market Size and Share in the 7MM (i.e. the United

LA JOLLA, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will be conducting one-on-one virtual meetings with institutional investors as part of the Lytham Partners Fall 2022 Investor Conference. The event is taking place virtually on September 28 - 29, 2022.

MediciNova (MNOV) said it will receive a new patent from the U.S. Patent and Trademark Office which covers MN-166 (ibudilast) to treat glioblastoma.The new patent is expected to expire…

Shares of MediciNova (NASDAQ: MNOV) were on an upswing in pre-market trading on Wednesday as the biopharmaceutical company received a Notice of Allowance from the Canadian Intellectual Property Office for its pending patent application. This patent application covered MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) which can be used for reducing cholesterol, trigyceride blood level and reducing low-density lipoprotein (LDL). Once the patent is issued, it is likely to be valid till July 2034. Kazuko Matsuda, M.D. Ph.D, MPH., Chief Medical Officer, MediciNova commented, "We are very pleased to receive notice that this new patent will be granted. As we already have patents for similar indications in the U.S.

MediciNova (MNOV) said it will get a from the Canadian Intellectual Property Office which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) to…

DelveInsight''s "Alcohol Use Disorder Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Alcohol Use Disorder Market Size and Share in the 7MM (i.e. the United

LA JOLLA, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will be conducting one-on-one virtual meetings with institutional investors as part of the Lytham Partners Fall 2022 Investor Conference. The event is taking place virtually on September 28 - 29, 2022.

MediciNova (MNOV) said it will receive a new patent from the U.S. Patent and Trademark Office which covers MN-166 (ibudilast) to treat glioblastoma.The new patent is expected to expire…

Shares of MediciNova (NASDAQ: MNOV) were on an upswing in pre-market trading on Wednesday as the biopharmaceutical company received a Notice of Allowance from the Canadian Intellectual Property Office for its pending patent application. This patent application covered MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) which can be used for reducing cholesterol, trigyceride blood level and reducing low-density lipoprotein (LDL). Once the patent is issued, it is likely to be valid till July 2034. Kazuko Matsuda, M.D. Ph.D, MPH., Chief Medical Officer, MediciNova commented, "We are very pleased to receive notice that this new patent will be granted. As we already have patents for similar indications in the U.S.

MediciNova (MNOV) said it will get a from the Canadian Intellectual Property Office which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) to…

DelveInsight''s "Alcohol Use Disorder Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Alcohol Use Disorder Market Size and Share in the 7MM (i.e. the United

LA JOLLA, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will be conducting one-on-one virtual meetings with institutional investors as part of the Lytham Partners Fall 2022 Investor Conference. The event is taking place virtually on September 28 - 29, 2022.

MediciNova (MNOV) said it will receive a new patent from the U.S. Patent and Trademark Office which covers MN-166 (ibudilast) to treat glioblastoma.The new patent is expected to expire…

Shares of MediciNova (NASDAQ: MNOV) were on an upswing in pre-market trading on Wednesday as the biopharmaceutical company received a Notice of Allowance from the Canadian Intellectual Property Office for its pending patent application. This patent application covered MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) which can be used for reducing cholesterol, trigyceride blood level and reducing low-density lipoprotein (LDL). Once the patent is issued, it is likely to be valid till July 2034. Kazuko Matsuda, M.D. Ph.D, MPH., Chief Medical Officer, MediciNova commented, "We are very pleased to receive notice that this new patent will be granted. As we already have patents for similar indications in the U.S.

MediciNova (MNOV) said it will get a from the Canadian Intellectual Property Office which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) to…